1. Opening Hook
Growing is commitment, they say. In Q2 FY26, Lincoln Pharma committed to growth—and profits politely stepped aside. While markets were busy chasing AI buzzwords and midcap adrenaline, Lincoln showed up with a very old-school pharma story: stable revenues, expanding plants, global ambitions, and margins… well, catching their breath.
Net profit slid, EBITDA sulked, and EPS quietly followed—yet management sounded anything but worried. Why? Because when you’re exporting to 60+ countries, entering Canada, eyeing 90 markets, and dreaming of ₹1,000 crore revenue, a weak quarter is just “transitory.”
Solar-powered plants, bulk drugs, cephalosporins, lifestyle therapies—there’s a lot simmering under the hood. The numbers look boring now, but the strategy hints at something louder later.
Stick around. The interesting bits aren’t in the headline numbers—they’re buried in management optimism and future promises.
2. At a Glance
- Revenue flat YoY: ₹170.6 cr—apparently growth took a tea break.
- EBITDA down 15%: Operating leverage forgot to show up.
- PAT fell 24%: Profits clearly didn’t get the growth memo.
- Exports at 55.8%: Geography doing more heavy lifting than margins.
- Dividend ₹1.80/share: Even weak quarters get pocket money.
3. Management’s Key Commentary
“We are targeting ₹1,000 crore revenue in the next three years.”
(Translation: This quarter doesn’t matter, trust the dream 😏)
“Growth will be driven by cardiac, diabetic, dermatology and ENT segments.”
(Lifestyle diseases = lifestyle revenues)
“Cephalosporin plant expansion is complete with expected ₹150 crore sales in 2–3 years.”
(Capex today, payoff tomorrow—classic pharma patience)
“We have commenced bulk drug manufacturing with approvals for 10 products.”
(Backward integration, because margins need rescuing)
“Exports will expand from 60 to over 90 countries.”
(More passports, same balance sheet for now)
“Company remains net-debt free with strong liquidity.”
(At
